Skip to main content

Table 1 Baseline demographics and characteristics, and clinical and comparative polysomnographic data from two subgroups of subjects.

From: Discontinuation of hypnotics during cognitive behavioural therapy for insomnia

 

Hypnotics non-abusing

(N = 13)

Hypnotics-abusing

(N = 15)

Significance

Age [years]

45.23 (s.d. 14.53)

42.27 (s.d. 13.54)

p = 0.58a

Gender [female : male]

9 : 4

10 : 5

p = 0.60b

Duration of disorder [insomnia length in months]

48 (IQR 17–204)*

60 (IQR 24–147)*

p = 0.62c

Insomnia Severity Index [ISI]

16.54 (s.d. 4.19)

18.67 (s.d. 4.93)

p = 0.23a

Epworth Sleepiness Scale [ESS]

12.15 (s.d. 5.83)

11.40 (s.d. 4.88)

p = 0.71a

Beck Depression Inventory [BDI]

7.0 (IQR 2–11)*

6.5 (IQR 2.0–9.25)*

p = 0.56c

Beck Anxiety Inventory [BAI]

10.31 (s.d. 6.21)

9.87 (s.d. 6.79)

p = 0.86a

Hamilton Rating Scale for Depression [HAMD]

7.85 (s.d. 3.36)

5.80 (s.d. 3.38)

p = 0.12a

modified Clinical Global Impression Severity [mCGI-S]

10 (IQR 9–11)*

8 (IQR 7–10)*

p = 0.18c

Total sleep time TST [min]

344.69 (s.d. 58.14)

292.63 (s.d. 143.06)

p = 0.23a

Sleep latency SL [min]

26.0 (IQR 7.15–47.45)*

27.2 (IQR 12.63–45.94)*

p = 0.72c

Sleep efficiency SE [%]

75.5 (IQR 63.5–82.0)*

72.0 (IQR 64.0–81.0)*

p = 0.86c

Wake after sleep onset WASO [min]

72.42 (s.d. 55.84)

87.37 (s.d. 58.72)

p = 0.50a

Stage 1 [min]

36.50 (s.d. 19.74)

31.90 (s.d. 24.50)

p = 0.59a

Stage 2 [min]

153.96 (s.d. 82.50)

154.37 (s.d. 40.50)

p = 0.98a

Stage 3+4 [min]

105.40 (s.d. 51.00)

120.74 (s.d. 44.50)

p = 0.04 a

REM [min]

55.90 (s.d. 45.00)

76.77 (s.d. 39.00)

p = 0.04 a

  1. * Data are presented as median (interquartile range) due to non-normal data distribution. Characters in bold indicate significance (p < 0.05).
  2. a – One-way ANOVA; b – Fischer Exact Test; c – Mann-Whitney U Test;
  3. IQR – interquartile range; s.d. – standard deviation; N.S. – non significant